SELLAS Life Sciences Group, Inc. (SLS) has 20 détenteurs institutionnels et initiés connus enregistrés. Le plus grand détenteur est CYTRX CORP avec 5,093,881 actions. Parmi les autres détenteurs notables Stergiou Angelos M. et CICIC DRAGAN.
Au cours des 12 derniers mois, les initiés ont effectué 14 transactions sur SLS l'action — 11 achats (d'une valeur de $185.41K) et 0 ventes (d'une valeur de RSU Award). Les achats d'initiés ont dépassé les ventes durant cette période, ce qui peut signaler une confiance dans les perspectives de l'entreprise.
SLS Participations des Initiés
Principal Actionnaire
CYTRX CORP
5,093,881 actions
Achats (12 mois)
11
$185.41K valeur
Ventes (12 mois)
0
$0.00 valeur
Activité de transactions (12 mois)
Principaux actionnaires initiés
| # |
Nom |
Rôle |
Actions détenues |
Dernière déclaration |
Taille relative |
| 1 |
Cytrx Corp |
10 Percent Owner |
5,093,881 |
2010-07-02 |
|
| 2 |
Stergiou Angelos M. |
President and CEO |
686,966 |
2025-12-05 |
|
| 3 |
Cicic Dragan |
SVP, Chief Development Officer |
557,805 |
2026-01-09 |
|
| 4 |
Burns John Thomas |
CFO |
554,327 |
2026-01-09 |
|
| 5 |
Stergiou Andelos M. |
President and CEO |
450,135 |
2017-12-29 |
|
| 6 |
Mazanet Rosemary |
Chief Medical Officer |
450,000 |
2013-01-31 |
|
| 7 |
Schwartz Mark W. |
President & CEO |
439,978 |
2016-07-06 |
|
| 8 |
Kalin Katherine Bach |
Director |
154,400 |
2026-01-09 |
|
| 9 |
Pavco Pamela |
Other: Former VP Pharma Development |
150,000 |
2011-09-27 |
|
| 10 |
Khvorova Anastasia |
Other: Former CSO |
137,482 |
2011-09-27 |
|
| 11 |
Ahn Mark J |
President & CEO |
116,225 |
2014-07-02 |
|
| 12 |
Kriegsman Steven A |
Director |
100,000 |
2015-06-23 |
|
| 13 |
Beerman Noah D |
CEO and President |
92,994 |
2011-03-17 |
|
| 14 |
Wasman Jane |
Director |
92,900 |
2026-01-09 |
|
| 15 |
Van Nostrand Robert L |
Director |
82,900 |
2026-01-09 |
|
| 16 |
Scheinberg David A |
Director |
73,082 |
2026-01-09 |
|
| 17 |
Varian John |
Director |
72,900 |
2026-01-09 |
|
| 18 |
Hillsberg Sanford |
Director |
56,950 |
2017-10-10 |
|
| 19 |
Gorder Mark Stephen |
President and CEO |
50,000 |
2005-03-31 |
|
| 20 |
Sarlis Nicholas J. |
Chief Medical Officer and SVP |
50,000 |
2019-03-18 |
|
Transactions récentes (12 derniers mois)
| Date |
Nom |
Rôle |
Type |
Actions |
Prix |
Valeur |
| 2026-01-07 |
Kalin Katherine Bach |
Director |
Attribution de RSU |
50,000 |
- |
- |
| 2026-01-07 |
Burns John Thomas |
CFO |
Attribution de RSU |
300,000 |
- |
- |
| 2026-01-07 |
Cicic Dragan |
SVP, Chief Development Officer |
Attribution de RSU |
300,000 |
- |
- |
| 2026-01-07 |
Varian John |
Director |
Attribution de RSU |
50,000 |
- |
- |
| 2026-01-07 |
Wasman Jane |
Director |
Attribution de RSU |
50,000 |
- |
- |
| 2026-01-07 |
Scheinberg David A |
Director |
Attribution de RSU |
50,000 |
- |
- |
| 2026-01-07 |
Van Nostrand Robert L |
Director |
Attribution de RSU |
50,000 |
- |
- |
| 2025-12-03 |
Stergiou Angelos M. |
President and CEO |
Autre (Vente) |
187,066 |
$1.50 |
$280.6K |
| 2025-12-03 |
Burns John Thomas |
CFO |
Autre (Vente) |
58,592 |
$1.50 |
$87.89K |
| 2025-12-03 |
Cicic Dragan |
SVP, Chief Development Officer |
Autre (Vente) |
63,800 |
$1.50 |
$95.7K |
| 2025-11-19 |
Kalin Katherine Bach |
Director |
Achat Informatif |
63,400 |
$1.59 |
$100.81K |
| 2025-06-12 |
Van Nostrand Robert L |
Director |
Achat Informatif |
10,000 |
$1.48 |
$14.8K |
| 2025-05-30 |
Wasman Jane |
Director |
Achat Informatif |
20,000 |
$1.69 |
$33.8K |
| 2025-05-22 |
Kalin Katherine Bach |
Director |
Achat Informatif |
20,000 |
$1.80 |
$36K |
Les autres consultent aussi